The size of the global cytokine-based therapies and inhibitors market is estimated to grow at a healthy CAGR during the forecast period.
Cytokines are the molecular messengers that allow communication with the immune system cells to generate a coordinated, robust but self-limited response to the targeted antigen. Cytokines provide various benefits; unlike in chemical drugs, a specific protein that mediates the inflammatory process can be inhibited. Cytokine inhibitors include antagonists, soluble receptors, cytokine binding proteins, and the cytokine that blocks other cytokines. The treatment for immune-mediated medical illnesses, including cancer and viral infections, can be done using Immunomodulatory, anti-viral, antiproliferative properties, cytokine interferon-alpha interleukin (IL).
The cytokine-based therapies can provide novel treatments for cancer, autoimmune diseases, and many types of infectious diseases. Various factors have limited the clinical potential of cytokines as drugs. FDA partnership was made with the New York Academy of Sciences to host a forum to discuss practical ways to harness the clinical potential of cytokines and cytokine antagonists as therapeutic agents.
MARKET DRIVERS:
Cytokine-based therapies have the potential to provide treatments for autoimmune diseases and cancer. Intercellular messengers activate signaling pathways in virtually all cell types. Rising research and development for understanding the mechanics and technological advancements in the immunological and therapeutics applications are anticipated to propel the market growth of the cytokine-based Therapies and Inhibitors Market. Increasing interest in harnessing the immune system to eradicate cancer will crease demand for the market. Vast signaling networks to develop cancer treatments are expected to raise market growth. Several animal tumor model studies have displayed that cytokines have a broad anti-tumor activity translated into several cytokine-based approaches for cancer therapy which is expected to drive the market growth. Cytokines are finding growing acceptance in cancer therapy all over the world.
MARKET RESTRAINTS:
The Cytokine Based Therapies and Inhibitors Market has some restraining factors that are restraining market growth, such as scarcity of skilled professionals for cytokine treatments for autoimmune diseases and cancer across the world; high cost of therapies are expected to impede the market growth.
Impact of COVID-19 on Cytokine Based Therapies and Inhibitors Market:
The covid-19 is a global pandemic, which was first identified in Wuhan, China. The world health organization announced the COVID-19 as the emergence of healthcare. It is an infectious disease, spread quickly from person to person. All the governments had declared nationwide lockdown and a ban on transportation and flights to control the spread.
COVID 19 disrupted the global economy in an unprecedented way. Many country's government authorities had imposed lockdown restrictions that disturbed the supply chain and manufacturing units with the coronavirus's surging cases.
However, the current evidence represents that severely ill patients tend to have a high concentration of proinflammatory cytokines. The high level of cytokines also shows a poor prognosis in COVID-19. Also, excessive infiltration of proinflammatory cells, including macrophages and T-helper 17 cells, has been found in lung tissues of coronavirus patients by post-mortem examination. As per the reports, cytokine storms may contribute to the mortality of COVID-19. The cytokines-based therapies and inhibitors market is anticipated to witness higher growth in the forecast period.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Type, Therapeutic Application, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on the global cytokine-based therapies and inhibitors market has been segmented and sub-segmented based on the type, therapeutic application, and region.
Cytokine Based Therapies and Inhibitors Market – By Type:
Based on the type, the interleukins segment is expected to dominate the global cytokine-based therapies and inhibitors market during the forecast period. Interleukins are a group of cytokines that were first seen to be expressed by white blood cells. Interleukins regulate cell growth, differentiation, and mobility, are essential in stimulating immune responses like inflammation. The increasing global prevalence of autoimmune disorders, increasing geriatric population, and advanced technologies in novel interleukins inhibitors are projected to increase the market growth.
Cytokine Based Therapies and Inhibitors Market – By Therapeutic Application:
Based on the therapeutic application, the inflammatory and immune disorders segment accounted for the largest share in the global market during the forecast period. The sign of an autoimmune disease is inflammation which causes redness, pain, and swelling. The disorders also have flare-ups when they get worse and in remission. An increase in the autoimmune system incidence, rise in the adoption of autoimmune disease therapeutics, and growing R&D activities to develop ideal therapeutics are the major driving factors of the inflammatory and immune disorders market.
Cytokine Based Therapies and Inhibitors Market – By Region:
Geographically, North America leads the global cytokine-based therapies and inhibitors market due to many companies in Cytokine Based Therapies and Inhibitors and increasing government investments. The North American Cytokine Based Therapies and Inhibitors Market growth is majorly driven by the factors such as the increasing prevalence of cancer. According to the American cancer society, it was estimated there were 1,762,450 new cancer cases and 606,880 diagnosed cancer deaths in the United States, which are anticipated to rise in the future. Moreover, increasing R&D activities of cancer therapies with lesser side effects are expected to create demand for cytokine-based treatments through which market expansion is possible.
In 2019, the European market had accounted for a substantial share globally and was estimated to register healthy CAGR during the market forecast period. The market growth can be increased by the factors such as growing interest among the people in harnessing the immune system to eradicate cancer.
The Asia Pacific is the fastest-growing market segment due to the growing awareness and increasing collaborations with western companies in China and the well-established biotechnology industries in Japan.
The Latin American market is expected to have steady growth with an increasing compound annual growth rate (CAGR). The players are technological advancements in immunological and therapeutics applications and are anticipated to propel cytokine-based market growth.
Middle East Africa held a moderate share of the Cytokine Based Therapies and Inhibitors Market. The market had a portion of the global market in 2020. However, Middle East Africa is projected to increase its growth during the forecast period.
KEY MARKET PARTICIPANTS:
Some of the prominent companies leading the global cytokine-based therapies and inhibitors market profiled in this report are GlaxoSmithKline LLC, AbbVie Inc., Eli Lilly and Company, Genentech, Inc., Immunochemistry Technologies LLC, Roche Diagnostics, Novartis, Merck Sharp & Dohme Corp., Johnson & Johnson, and Amgen Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Interleukins
5.1.3 Tumor necrosis factor
5.1.4 Epidermal growth factor
5.1.5 Interferon
5.1.6 Chemokine
5.1.7 Y-o-Y Growth Analysis, By Type
5.1.8 Market Attractiveness Analysis, By Type
5.1.9 Market Share Analysis, By Type
5.2 Therapeutic Application
5.2.1 Introduction
5.2.2 Inflammatory and immune disorders
5.2.3 Cancer and malignancies
5.2.4 Infectious diseases
5.2.5 Others
5.2.6 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.7 Market Attractiveness Analysis, By Therapeutic Application
5.2.8 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Therapeutic Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Therapeutic Application
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 GlaxoSmithKline LLC
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AbbVie Inc.
8.3 Eli Lilly and Company
8.4 Genentech, Inc
8.5 Immunochemistry Technologies LLC
8.6 Roche Diagnostics
8.7 Novartis
8.8 Merck Sharp & Dohme Corp
8.9 Johnson & Johnson
8.10 Amgen Inc
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
